151751-Najiba-Chargi

100 CHAPTER 6 Table 2. All postoperative complications Postoperative complications All patients N = 78 N (%) Low SMM N = 48 N (%) Without SMM N = 30 N (%) CD 0 17 (21.8) 9 (18.8) 8 (26.7) CD I - II Wound dehiscence Wound infection Pulmonary embolism Blood transfusion Pneumonia 36 (46.2) 12 13 1 9 1 20 (41.7) 16 (53.3) CD III - IV ICU admission Need for surgical intervention (e.g., necrosectomy, drainage of hematoma) 25 (32.1) 9 16 19 (39.6) 6 (20.0) FFF related complications Congestion Partial skin paddle necrosis Flap dehiscence Thrombosis Failure 5 6 4 2 1 5 (38.5) 3 (23.1) 2 (15.4) 2 (15.4) 1 (7.7) 0 (0.0) 3 (60.0) 2 (40.0) 0 (0.0) 0 (0.0) SURVIVAL ANALYSIS Median follow-up time was 36months (IQR 13-62months). At the time of concluding this study, 38 (48.7%) patients of the cohort had died of any cause and 40 (51.3%) were alive. As seen in figure 2, patients with low SMM showed a significant lower median OS (26 months; IQR 10-62) compared to patients without low SMM (48 months; IQR 20-79) (Log rank χ 2= 4.76; p=0.03). Patients with low SMM had a significantly decreased 5-year OS rate compared to patients without low SMM (41% versus 71%; p=0.03). No significant differences were seen in median DFS between patients with low SMM (22 months; IQR 6-61) and patients without low SMM (48 months; IQR 20-79) (Log rank χ 2= 2.54; p=0.11) (figure 3). Table 3. shows the results of the univariate and multivariate Cox regression analysis for OS and DFS. In univariate Cox regression analysis, low SMM andmild-moderate ACE-27 score were significant prognosticators for OS. In multivariable Cox regression analyses corrected for age at time of operation, ACE-27 score and TNM stage, low SMM remained a significant negative prognostic factor for OS (HR 2.4; 95% CI 1.1-5.1; p=0.02).